Virology Contract Research Laboratory

Specialized team of scientists

BSL 2 & BSL 3 Facilities

Leading in Influenza

and other targets: RSV, MERS, Rabies

and other targets: Polio, Rhino, Entero

Large Scale Diagnostic Services

Specialized Consultancy Services

NEWS

ViroSpot MN assay, a novel tool for antigenic characterization of influenza viruses and serology.
The ViroSpot assay platform is currently available for influenza virus and RSV, and under development for multiple other viral targets.

Virology Contract Research Laboratory

Specialized team of scientists

BSL 2 & BSL 3 Facilities

Leading in Influenza

and other targets: ZIKA, Dengue, Chikungunya

and other targets: VZV, HSV, HPV

Large Scale Diagnostic Services

Specialized Consultancy Services

NEWS

ViroSpot MN assay, a novel tool for antigenic characterization of influenza viruses and serology.
The ViroSpot assay platform is currently available for influenza virus and RSV, and under development for multiple other viral targets.

World Vaccine Congress 2018, Washington

Our Contribution

During the conference, Viroclinics Biosciences’ experts will shed light on the topic “Transmission of Human Respiratory Syncytial Virus in the Immunocompromised Ferret Model”. During our presentation on April 4th, we will discuss the following topics:

  • Demonstration of efficient transmission of human respiratory syncytial virus (HRSV) from immunocompromised ferrets to both immunocompromised and immunocompetent ferrets.
  • Research findings were collected by applying several assays including Sequencing, PCR, Virus Culture/Titration. Furthermore, histo pathological changes of respiratory tissues from donor and contact ferrets were demonstrated by standard and immunohistochemistry.
  • A high transmission rate of HRSV was found and more …

Furthermore, we will present our views on how R&D outsourcing can stimulate the innovation processes for vaccine developers. Practical case examples will be discussed and new horizons will be explored by sharing our latest insights on RSV, and other viral targets in our booth # 113.

We are looking forward to sharing our latest insights with you during the World Vaccine Washington Conference.

Speaker

Dr Koert Stittelaar, Director Preclinical Services

Dr Koert Stittelaar joined Viroclinics Biosciences in 2006. Previous to this he was a Postdoc at the Virology Department at Erasmus MC Rotterdam in vaccine and pathogenesis research projects including HIV, dengue and poxvirus preclinical research. Koert was trained in medical microbiology at the National Institute of Public Health and University of Utrecht working on Neisseria meningitidis-specific T cell responses. Koert defended his PhD thesis in 2001: “Vaccination against Measles” at the Erasmus University Rotterdam. His start at Viroclinics Biosciences boosted the Preclinical Service activities within the company. He gained expertise in the field of influenza virus and RSV intervention strategy research and is now mainly concerned with containment of highly pathogenic viruses, model development and project acquisition like polio virus related projects. Koert has authored many publications.

Contact Speaker

OUR LATEST NEWS

Parcom Capital acquires Viroclinics Biosciences

Parcom Capital has acquired the successful clinical research organisation Viroclinics Biosciences. Viroclinics believes Parcom is the perfect partner to help it realise its growth ambitions.

↓